A method for detecting a neurodegenerative disorder that is amyotrophic lateral sclerosis in a subject, which method comprises: a) a1) measuring the level for an miRNA pair in a bodily fluid sample collected from the subject selected from the group consisting of miR-206 / miR-31, miR-206 / miR-129-3p, miR-206 / miR-138, miR-206 / miR-874, miR-206 / miR-125b, miR-206 / miR-204, miR-206 / miR-29a, miR-206 / miR-155, miR-206 / miR-338-3p, miR-206 / miR-16, miR-206 / miR-451, miR-206 / miR-218, miR-99b / miR-155,, miR-181a / miR-338-3p, miR-335 / miR-338-3p, miR-7 / miR-31, miR-9* / miR-338-3p, and miR-99b / miR-128a; or a2) measuring the level for one or more miRNA pair combinations in a bodily fluid sample collected from the subject selected from the group consisting of miR-206 / miR-31 + miR-99b / miR-338-3p, miR-206 / miR-138 + miR-9* / miR-129-3p, miR-206 / miR-31 + miR-335 / miR-338-3p, miR-206 / miR-16 + miR-335 / miR-338-3p, miR-9* / miR-129-3p + miR-99b / miR-338-3p, miR-206 / miR-204 + miR-206 / miR-218 + miR-335 / miR-338-3p, miR-206 / miR-204 + miR-206 / miR-218 + miR-9* / miR-129-3p, miR-206 / miR-338-3p + miR-99b / miR-129-3p + miR-335 / miR-338-3p, miR-206 / miR-338-3p + miR-99b / miR-155 + miR-335 / miR-338-3p and miR-181a / miR-338-3p + miR-335 / miR-338-3p + miR-7 / miR-31 + miR-7 / miR-129-3p; or a3) wherein the subject is a male, measuring the level for an miRNA pair combination of miR-206 / miR-155 + miR-9* / miR-129-3p + miR-355 / miR-338-3p; or wherein the subject is a female, measuring the level for an miRNA pair combination of miR-206 / miR-7 + miR-9* / miR-125b + miR-491 / miR-204; b) comparing the ratio of the levels of the miRNAs calculated in step (a) with a corresponding control ratio, and c) (i) identifying the subject as being afflicted with ALS when the ratio of the levels of the miRNAs calculated in step (b) is higher than the corresponding control ratio or (ii) identifying the subject as not being afflicted with ALS when the ratio of the levels of the miRNA calculated in step (b) is not higher than the corresponding control ratio. a) a1) measuring the level for an miRNA pair in a bodily fluid sample collected from the subject selected from the group consisting of miR-206 / miR-31, miR-206 / miR-129-3p, miR-206 / miR-138, miR-206 / miR-874, miR-206 / miR-125b, miR-206 / miR-204, miR-206 / miR-29a, miR-206 / miR-155, miR-206 / miR-338-3p, miR-206 / miR-16, miR-206 / miR-451, miR-206 / miR-218, miR-99b / miR-155,, miR-181a / miR-338-3p, miR-335 / miR-338-3p, miR-7 / miR-31, miR-9* / miR-338-3p, and miR-99b / miR-128a; or a2) measuring the level for one or more miRNA pair combinations in a bodily fluid sample collected from the subject selected from the group consisting of miR-206 / miR-31 + miR-99b / miR-338-3p, miR-206 / miR-138 + miR-9* / miR-129-3p, miR-206 / miR-31 + miR-335 / miR-338-3p, miR-206 / miR-16 + miR-335 / miR-338-3p, miR-9* / miR-129-3p + miR-99b / miR-338-3p, miR-206 / miR-204 + miR-206 / miR-218 + miR-335 / miR-338-3p, miR-206 / miR-204 + miR-206 / miR-218 + miR-9* / miR-129-3p, miR-206 / miR-338-3p + miR-99b / miR-129-3p + miR-335 / miR-338-3p, miR-206 / miR-338-3p + miR-99b / miR-155 + miR-335 / miR-338-3p and miR-181a / miR-338-3p + miR-335 / miR-338-3p + miR-7 / miR-31 + miR-7 / miR-129-3p; or a3) wherein the subject is a male, measuring the level for an miRNA pair combination of miR-206 / miR-155 + miR-9* / miR-129-3p + miR-355 / miR-338-3p; or wherein the subject is a female, measuring the level for an miRNA pair combination of miR-206 / miR-7 + miR-9* / miR-125b + miR-491 / miR-204; a1) measuring the level for an miRNA pair in a bodily fluid sample collected from the subject selected from the group consisting of miR-206 / miR-31, miR-206 / miR-129-3p, miR-206 / miR-138, miR-206 / miR-874, miR-206 / miR-125b, miR-206 / miR-204, miR-206 / miR-29a, miR-206 / miR-155, miR-206 / miR-338-3p, miR-206 / miR-16, miR-206 / miR-451, miR-206 / miR-218, miR-99b / miR-155,, miR-181a / miR-338-3p, miR-335 / miR-338-3p, miR-7 / miR-31, miR-9* / miR-338-3p, and miR-99b / miR-128a; or a2) measuring the level for one or more miRNA pair combinations in a bodily fluid sample collected from the subject selected from the group consisting of miR-206 / miR-31 + miR-99b / miR-338-3p, miR-206 / miR-138 + miR-9* / miR-129-3p, miR-206 / miR-31 + miR-335 / miR-338-3p, miR-206 / miR-16 + miR-335 / miR-338-3p, miR-9* / miR-129-3p + miR-99b / miR-338-3p, miR-206 / miR-204 + miR-206 / miR-218 + miR-335 / miR-338-3p, miR-206 / miR-204 + miR-206 / miR-218 + miR-9* / miR-129-3p, miR-206 / miR-338-3p + miR-99b / miR-129-3p + miR-335 / miR-338-3p, miR-206 / miR-338-3p + miR-99b / miR-155 + miR-335 / miR-338-3p and miR-181a / miR-338-3p + miR-335 / miR-338-3p + miR-7 / miR-31 + miR-7 / miR-129-3p; or a3) wherein the subject is a male, measuring the level for an miRNA pair combination of miR-206 / miR-155 + miR-9* / miR-129-3p + miR-355 / miR-338-3p; or wherein the subject is a female, measuring the level for an miRNA pair combination of miR-206 / miR-7 + miR-9* / miR-125b + miR-491 / miR-204; b) comparing the ratio of the levels of the miRNAs calculated in step (a) with a corresponding control ratio, and c) (i) identifying the subject as being afflicted with ALS when the ratio of the levels of the miRNAs calculated in step (b) is higher than the corresponding control ratio or (ii) identifying the subject as not being afflicted with ALS when the ratio of the levels of the miRNA calculated in step (b) is not higher than the corresponding control ratio.